The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Inherited Predispositions to Myeloid Neoplasms: Pathogenesis and Clinical Implications
Abstract
Myeloid neoplasms with and without preexisting platelet disorders frequently develop in association with an underlying germline predisposition. Germline alterations affecting ANKRD26 , CEBPA , DDX41 , ETV6 , and RUNX1 are associated with nonsyndromic predisposition to the development of myeloid neoplasms including acute myeloid leukemia and myelodysplastic syndrome. However, germline predisposition to myeloid neoplasms is also associated with a wide range of other syndromes, including SAMD9 / 9L associated predisposition, GATA2 deficiency, RASopathies, ribosomopathies, telomere biology disorders, Fanconi anemia, severe congenital neutropenia, Down syndrome, and others. In the fifth edition of the World Health Organization (WHO) series on the classification of tumors of hematopoietic and lymphoid tissues, myeloid neoplasms associated with germline predisposition have been recognized as a separate entity. Here, we review several disorders from this WHO entity as well as other related conditions with an emphasis on the molecular pathogenesis of disease and accompanying somatic alterations. Finally, we provide an overview of establishing the molecular diagnosis of these germline genetic conditions and general recommendations for screening and management of the associated hematologic conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another common feature of these diseases is the increased risk of developing AML, MDS, and other types of cancer [149, 156].”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [149]
In the citing paper
“The second common trait is impaired hematopoiesis leading to anemia and BMF [149, 154].”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [149]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917
Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100
Telomere end-replication problem and cell aging
Levy, M. Z., Allsopp, R. C., Futcher, A. B., Greider, C. W., & Harley, C. B. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90096-3 · Cited by 1,069
Impaired Energy Homeostasis in C/EBPα Knockout Mice
Wang, N.-D., Finegold, M. J., Bradley, A., Ou, C. N., Abdelsayed, S. V., Wilde, M. D., Taylor, L. R., Wilson, D. R., & Darlington, G. J. (1995) · Science · doi:10.1126/science.7652557 · Cited by 929
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910
Hewitt, G., Jurk, D., Marques, F. D. M., Correia-Melo, C., Hardy, T., Gackowska, A., Anderson, R., Taschuk, M., Mann, J., & Passos, J. F. (2012) · Nature Communications · doi:10.1038/ncomms1708 · Cited by 908
Pabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G. (2001) · Nature Genetics · doi:10.1038/85820 · Cited by 901
Shelterin-Mediated Telomere Protection
de Lange, T. (2018) · Annual Review of Genetics · doi:10.1146/annurev-genet-032918-021921 · Cited by 816
Ichikawa, M., Asai, T., Saito, T., Yamamoto, G., Seo, S., Yamazaki, I., Yamagata, T., Mitani, K., Chiba, S., Hirai, H., et al. (2004) · Nature Medicine · doi:10.1038/nm997 · Cited by 596
Determinants of telomere length across human tissues
Demanelis, K., Jasmine, F., Chen, L. S., Chernoff, M., Tong, L., Delgado, D., Zhang, C., Shinkle, J., Sabarinathan, M., Lin, H., et al. (2020) · Science · doi:10.1126/science.aaz6876 · Cited by 515
Research works printed but not linked: 203
- 2017, RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM), Semin. Hematol., 54, 75, 10.1053/j.seminhematol.2017.04.006 · DOI
- 2023, Hereditary platelet disorders associated with germ line variants in RUNX1, ETV6, and ANKRD26, Blood, 141, 1533, 10.1182/blood.2022017735 · DOI
- 2020, RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML, Blood Adv, 4, 1131, 10.1182/bloodadvances.2019000901 · DOI · Paper page
- 2020, High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML, Blood, 135, 1882, 10.1182/blood.2019003357 · DOI
- 2021, RUNX1 germline variants in RUNX1-mutant AML: how frequent?, Blood, 137, 1428, 10.1182/blood.2020008478 · doi:10.1182/blood.2020008478
- 2016, RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features, Leukemia, 30, 2160, 10.1038/leu.2016.126 · DOI · Paper page
- 2012, RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures, J. Clin. Oncol., 30, 3109, 10.1200/JCO.2011.40.6652 · DOI · Paper page
- 2024, Haematolymphoid Tumours, Part A, 11
- 2023, A critical role of RUNX1 in governing megakaryocyte-primed hematopoietic stem cell differentiation, Blood Adv, 7, 2590, 10.1182/bloodadvances.2022008591 · DOI
- 2010, Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis, Blood, 115, 1610, 10.1182/blood-2009-07-232249 · DOI
- 2007, Isoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1, PLOS Med, 4, e172, 10.1371/journal.pmed.0040172 · DOI
- 2011, Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families, Blood, 117, 6673, 10.1182/blood-2011-02-336537 · DOI · Paper page
- 2011, Mutations in the 5′ UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2, Am. J. Hum. Genet., 88, 115, 10.1016/j.ajhg.2010.12.006 · DOI · Paper page
- 2013, ANKRD26-related thrombocytopenia and myeloid malignancies, Blood, 122, 1987, 10.1182/blood-2013-04-499319 · DOI · Paper page
- 2014, Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation, J. Clin. Investig., 124, 580, 10.1172/JCI71861 · DOI · Paper page
- 2015, Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia, Nat. Genet., 47, 535, 10.1038/ng.3253 · DOI · Paper page
- 2015, Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy, Nat. Genet., 47, 180, 10.1038/ng.3177 · DOI · Paper page
- 2021, Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia, Blood, 137, 364, 10.1182/blood.2020006164 · DOI
- 2001, TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3, Oncogene, 20, 3716, 10.1038/sj.onc.1204479 · DOI · Paper page
- 1998, The ets family member Tel binds to the Fli-1 oncoprotein and inhibits its transcriptional activity, J. Biol. Chem., 273, 17525, 10.1074/jbc.273.28.17525 · DOI
- 2004, Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival, Genes Dev, 18, 2336, 10.1101/gad.1239604 · DOI · Paper page
- 1998, The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow, Genes Dev, 12, 2392, 10.1101/gad.12.15.2392 · DOI · Paper page
- 2022, ETV6-related thrombocytopenia: dominant negative effect of mutations as common pathogenic mechanism, Haematologica, 107, 2249, 10.3324/haematol.2022.280729 · DOI
- 2015, Disease evolution and outcomes in familial AML with germline CEBPA mutations, Blood, 126, 1214, 10.1182/blood-2015-05-647172 · DOI · Paper page
- 2016, Whole exome sequencing reveals a C-terminal germline variant in CEBPA-associated acute myeloid leukemia: 45-year follow up of a large family, Haematologica, 101, 846, 10.3324/haematol.2015.130799 · DOI
- 2009, Complexity of CEBPA dysregulation in human acute myeloid leukemia, Clin. Cancer Res., 15, 5303, 10.1158/1078-0432.CCR-08-2941 · DOI
- 2017, Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation, Blood, 129, 2083, 10.1182/blood-2016-09-687822 · DOI · Paper page
- 2014, Granulopoiesis requires increased C/EBPα compared to monopoiesis, correlated with elevated Cebpa in immature G-CSF receptor versus M-CSF receptor expressing cells, PLOS ONE, 9, e95784, 10.1371/journal.pone.0095784 · DOI
- 2014, CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation, Sci. Rep., 4, 4261, 10.1038/srep04261 · DOI
- 1993, CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials, PNAS, 90, 8219, 10.1073/pnas.90.17.8219 · DOI · Paper page
- 1994, Translation start site multiplicity of the CCAAT/enhancer binding protein α mRNA is dictated by a small 5′ open reading frame, Nucleic Acids Res, 22, 5540, 10.1093/nar/22.25.5540 · DOI
- 1996, Evidence for posttranscriptional regulation of C/EBPα and C/EBPβ isoform expression during the lipopolysaccharide-mediated acute-phase response, Mol. Cell. Biol., 16, 2295, 10.1128/MCB.16.5.2295 · DOI
- 2023, Germ line DDX41 mutations define a unique subtype of myeloid neoplasms, Blood, 141, 534, 10.1182/blood.2022018221 · DOI
- 2015, Inherited and somatic defects in DDX41 in myeloid neoplasms, Cancer Cell, 27, 658, 10.1016/j.ccell.2015.03.017 · DOI · Paper page
- 2023, The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia, Virchows Arch, 482, 113, 10.1007/s00428-022-03447-9 · DOI
- 2022, AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome, Leukemia, 36, 664, 10.1038/s41375-021-01404-0 · DOI
- 2023, DDX41-associated susceptibility to myeloid neoplasms, Blood, 141, 1544, 10.1182/blood.2022017715 · DOI
- 2021, Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia, Cell Stem Cell, 28, 1966, 10.1016/j.stem.2021.08.004 · DOI
- 2015, Bruton's tyrosine kinase phosphorylates DDX41 and activates its binding of dsDNA and STING to initiate type 1 interferon response, Cell Rep, 10, 1055, 10.1016/j.celrep.2015.01.039 · DOI
- 2023, Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies, Blood Adv, 7, 549, 10.1182/bloodadvances.2022008172 · DOI
- 2022, Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia, Bone Marrow Transplant, 57, 1716, 10.1038/s41409-022-01776-6 · doi:10.1038/s41409-022-01776-6
- 2015, The genomic landscape of juvenile myelomonocytic leukemia, Nat. Genet., 47, 1326, 10.1038/ng.3400 · DOI · Paper page
- 2005, The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease, Blood, 106, 2183, 10.1182/blood-2005-02-0531 · DOI · Paper page
- 2022, The RASopathies: biology, genetics and therapeutic options, Adv. Cancer Res., 153, 305, 10.1016/bs.acr.2021.07.007 · DOI
- 2010, Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia, Nat. Genet., 42, 794, 10.1038/ng.641 · DOI · Paper page
- 2010, Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004–2006, Birth Defects Res. A Clin. Mol. Teratol., 88, 1008, 10.1002/bdra.20735 · DOI · Paper page
- 2000, Risks of leukaemia and solid tumours in individuals with Down's syndrome, Lancet, 355, 165, 10.1016/S0140-6736(99)05264-2 · DOI · Paper page
- 2007, Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome, Blood, 110, 2128, 10.1182/blood-2007-01-069542 · DOI
- 2014, Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group, Blood, 123, 70, 10.1182/blood-2013-06-509463 · DOI · Paper page
- 2008, Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome, Lancet, 372, 1484, 10.1016/S0140-6736(08)61341-0 · DOI · Paper page
- 2010, Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group, Blood, 115, 1006, 10.1182/blood-2009-08-235408 · DOI · Paper page
- 2021, Leukemia risk in a cohort of 3.9 million children with and without Down syndrome, J. Pediatr., 234, 172, 10.1016/j.jpeds.2021.03.001 · DOI
- 2008, Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations, Blood, 112, 4507, 10.1182/blood-2008-04-152967 · DOI · Paper page
- 2002, Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome, Nat. Genet., 32, 148, 10.1038/ng955 · DOI · Paper page
- 2022, Advances in molecular characterization of myeloid proliferations associated with Down syndrome, Front. Genet., 13, 891214, 10.3389/fgene.2022.891214 · DOI
- 2023, RUNX1 isoform disequilibrium promotes the development of trisomy 21-associated myeloid leukemia, Blood, 141, 1105, 10.1182/blood.2022017619 · DOI
- 1954, Congenital telangiectatic erythema resembling lupus erythematosus in dwarfs; probably a syndrome entity, AMA Am. J. Dis. Child, 88, 754
- 1974, Bloom's syndrome. III. Analysis of the chromosome aberration characteristic of this disorder, Chromosoma, 48, 361, 10.1007/BF00290993 · DOI
- 1977, Bloom's syndrome. IV. Sister-chromatid exchanges in lymphocytes, Am. J. Hum. Genet., 29, 248
- 2014, Human RecQ helicases in DNA repair, recombination, and replication, Annu. Rev. Biochem., 83, 519, 10.1146/annurev-biochem-060713-035428 · DOI · Paper page
- 2000, Association of the Bloom syndrome protein with topoisomerase IIIα in somatic and meiotic cells, Cancer Res, 60, 1162
- 2021, Bloom syndrome DNA helicase deficiency is associated with oxidative stress and mitochondrial network changes, Sci. Rep., 11, 2157, 10.1038/s41598-021-81075-0 · DOI
- 1998, Carrier frequency of the Bloom syndrome blm Ash mutation in the Ashkenazi Jewish population, Mol. Genet. Metab., 64, 286, 10.1006/mgme.1998.2733 · DOI
- 2011, Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome, Blood, 118, 2653, 10.1182/blood-2011-05-356352 · DOI · Paper page
- 2011, Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency, Blood, 118, 2656, 10.1182/blood-2011-06-360313 · DOI · Paper page
- 2011, Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia, Nat. Genet., 43, 1012, 10.1038/ng.913 · DOI · Paper page
- 2011, Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome), Nat. Genet., 43, 929, 10.1038/ng.923 · DOI · Paper page
- 2013, High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia, Blood, 121, 822, 10.1182/blood-2012-08-447367 · DOI · Paper page
- 2018, A landscape of germ line mutations in a cohort of inherited bone marrow failure patients, Blood, 131, 717, 10.1182/blood-2017-09-806489 · DOI · Paper page
- 2018, Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients, Haematologica, 103, 1278, 10.3324/haematol.2017.181909 · DOI · Paper page
- 2016, Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents, Blood, 127, 1387, 10.1182/blood-2015-09-669937 · DOI · Paper page
- 2023, Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41, Blood Adv, 7, 6092, 10.1182/bloodadvances.2023010045 · DOI
- 2011, Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications, Haematologica, 96, 1221, 10.3324/haematol.2011.041152 · DOI
- 2015, GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia, Blood, 125, 56, 10.1182/blood-2014-06-580340 · DOI · Paper page
- 1992, GATA-binding transcription factors in hematopoietic cells, Blood, 80, 575, 10.1182/blood.V80.3.575.575 · DOI · Paper page
- 2013, Gata2 cis-element is required for hematopoietic stem cell generation in the mammalian embryo, J. Exp. Med., 210, 2833, 10.1084/jem.20130733 · DOI
- 1994, An early haematopoietic defect in mice lacking the transcription factor GATA-2, Nature, 371, 221, 10.1038/371221a0 · DOI · Paper page
- 2005, Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis, Blood, 106, 477, 10.1182/blood-2004-08-2989 · DOI · Paper page
- 2004, GATA-2 plays two functionally distinct roles during the ontogeny of hematopoietic stem cells, J. Exp. Med., 200, 871, 10.1084/jem.20031556 · DOI · Paper page
- 2020, Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?, Blood Adv, 4, 4584, 10.1182/bloodadvances.2020002953 · DOI
- 2016, SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7, Nat. Genet., 48, 792, 10.1038/ng.3569 · DOI · Paper page
- 2016, Ataxia-pancytopenia syndrome is caused by missense mutations in SAMD9L, Am. J. Hum. Genet., 98, 1146, 10.1016/j.ajhg.2016.04.009 · DOI · Paper page
- 2017, Germline SAMD9 mutation in siblings with monosomy 7 and myelodysplastic syndrome, Leukemia, 31, 1827, 10.1038/leu.2017.142 · doi:10.1038/leu.2017.142
- 2017, The genomic landscape of pediatric myelodysplastic syndromes, Nat. Commun., 8, 1557, 10.1038/s41467-017-01590-5 · DOI · Paper page
- 2018, Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes, JCI Insight, 3, e121086, 10.1172/jci.insight.121086 · DOI
- 2021, Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes, Nat. Med., 27, 1806, 10.1038/s41591-021-01511-6 · DOI · Paper page
- 2018, Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes, Blood, 132, 2309, 10.1182/blood-2017-05-787390 · DOI
- 2020, Germline predisposition in myeloid neoplasms: unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes, Best Pract. Res. Clin. Haematol., 33, 101197, 10.1016/j.beha.2020.101197 · DOI
- 2021, Pediatric MDS and bone marrow failure-associated germline mutations in SAMD9 and SAMD9L impair multiple pathways in primary hematopoietic cells, Leukemia, 35, 3232, 10.1038/s41375-021-01212-6 · DOI
- 2017, Somatic mutations and progressive monosomy modify SAMD9-related phenotypes in humans, J. Clin. Investig., 127, 1700, 10.1172/JCI91913 · DOI · Paper page
- 2022, Mutant Samd9l expression impairs hematopoiesis and induces bone marrow failure in mice, J. Clin. Investig., 132, e158869, 10.1172/JCI158869 · DOI
- 2023, Human SAMD9 is a poxvirus-activatable anticodon nuclease inhibiting codon-specific protein synthesis, Sci. Adv., 9, eadh8502, 10.1126/sciadv.adh8502 · DOI
- 2019, An update on the biology and management of dyskeratosis congenita and related telomere biology disorders, Expert Rev. Hematol., 12, 1037, 10.1080/17474086.2019.1662720 · DOI · Paper page
- 1993, Dyskeratosis congenita and related telomere biology disorders
- 2017, Classical inherited bone marrow failure syndromes with high risk for myelodysplastic syndrome and acute myelogenous leukemia, Semin. Hematol., 54, 105, 10.1053/j.seminhematol.2017.04.004 · DOI
- 2023, Clinical manifestations of telomere biology disorders in adults, Hematol. Am. Soc. Hematol. Educ. Progr., 2023, 563, 10.1182/hematology.2023000490 · DOI
- 2012, Dyskeratosis congenita as a disorder of telomere maintenance, Mutat. Res., 730, 43
- 2011, Dyskeratosis congenita, Hematol. Am. Soc. Hematol. Educ. Progr., 2011, 480, 10.1182/asheducation-2011.1.480 · DOI · Paper page
- 2018, Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up, Haematologica, 103, 30, 10.3324/haematol.2017.178111 · DOI · Paper page
- 2015, Clinical utility gene card for: Dyskeratosis congenita – update 2015, Eur. J. Hum. Genet., 23, 558
- 2007, Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita, Blood, 110, 1439, 10.1182/blood-2007-02-075598 · DOI · Paper page
- 2012, Telomere length is associated with disease severity and declines with age in dyskeratosis congenita, Haematologica, 97, 353, 10.3324/haematol.2011.055269 · DOI · Paper page
- 2017, Telomeres in cancer: tumour suppression and genome instability, Nat. Rev. Mol. Cell Biol., 18, 175, 10.1038/nrm.2016.171 · DOI · Paper page
- 2021, Shaping human telomeres: from shelterin and CST complexes to telomeric chromatin organization, Nat. Rev. Mol. Cell Biol., 22, 283, 10.1038/s41580-021-00328-y · DOI · Paper page
- 2009, How telomeres solve the end-protection problem, Science, 326, 948, 10.1126/science.1170633 · DOI · Paper page
- 2023, Genetics of human telomere biology disorders, Nat. Rev. Genet., 24, 86, 10.1038/s41576-022-00527-z · DOI · Paper page
- 2014, In the end, what's the problem?, Mol. Cell, 53, 855, 10.1016/j.molcel.2014.03.008 · DOI
- 2022, Telomere-mediated lung disease, Physiol. Rev., 102, 1703, 10.1152/physrev.00046.2021 · DOI · Paper page
- 2022, Consequences of telomere replication failure: the other end-replication problem, Trends Biochem. Sci., 47, 506, 10.1016/j.tibs.2022.03.013 · DOI
- 2012, Removal of shelterin reveals the telomere end-protection problem, Science, 336, 593, 10.1126/science.1218498 · DOI · Paper page
- 2016, Understanding TERT promoter mutations: a common path to immortality, Mol. Cancer Res., 14, 315, 10.1158/1541-7786.MCR-16-0003 · DOI · Paper page
- 2021, Telomeres and cancer, Life, 11, 1405, 10.3390/life11121405 · DOI
- 1995, Telomere elongation in immortal human cells without detectable telomerase activity, EMBO J, 14, 4240, 10.1002/j.1460-2075.1995.tb00098.x · DOI · Paper page
- 2021, Structure of human telomerase holoenzyme with bound telomeric DNA, Nature, 593, 449, 10.1038/s41586-021-03415-4 · DOI · Paper page
- 1994, Specific association of human telomerase activity with immortal cells and cancer, Science, 266, 2011, 10.1126/science.7605428 · DOI · Paper page
- 2011, The role of telomeres in the ageing of human skin, Exp. Dermatol., 20, 297, 10.1111/j.1600-0625.2010.01242.x · DOI · Paper page
- 1996, Telomerase activity in human intestine, Int. J. Oncol., 9, 453
- 2016, Inhibition of telomerase RNA decay rescues telomerase deficiency caused by dyskerin or PARN defects, Nat. Struct. Mol. Biol., 23, 286, 10.1038/nsmb.3184 · DOI
- 2006, hNaf1 is required for accumulation of human box H/ACA snoRNPs, scaRNPs, and telomerase, RNA, 12, 832, 10.1261/rna.2344106 · DOI
- 2016, Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis-emphysema, Sci. Transl. Med., 8, 351ra107
- 2015, A polyadenylation-dependent 3′ end maturation pathway is required for the synthesis of the human telomerase RNA, Cell Rep, 13, 2244, 10.1016/j.celrep.2015.11.003 · DOI
- 2019, ZCCHC8, the nuclear exosome targeting component, is mutated in familial pulmonary fibrosis and is required for telomerase RNA maturation, Genes Dev, 33, 1381, 10.1101/gad.326785.119 · DOI
- 2021, Shaping human telomeres: from shelterin and CST complexes to telomeric chromatin organization, Nat. Rev. Mol. Cell Biol., 22, 283, 10.1038/s41580-021-00328-y · DOI · Paper page
- 2020, TINF2 is a haploinsufficient tumor suppressor that limits telomere length, eLife, 9, e61235, 10.7554/eLife.61235 · DOI
- 2014, Inherited bone marrow failure associated with germline mutation of ACD, the gene encoding telomere protein TPP1, Blood, 124, 2767, 10.1182/blood-2014-08-596445 · DOI
- 2015, Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma, J. Natl. Cancer Inst., 107, dju408
- 2016, Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia, Blood, 128, 2319, 10.1182/blood-2016-01-695692 · DOI
- 2013, POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia, Nat. Genet., 45, 526, 10.1038/ng.2584 · DOI · Paper page
- 2017, The wide spectrum of POT1 gene variants correlates with multiple cancer types, Eur. J. Hum. Genet., 25, 1278, 10.1038/ejhg.2017.134 · DOI
- 2016, A POT1 mutation implicates defective telomere end fill-in and telomere truncations in Coats plus, Genes Dev, 30, 812, 10.1101/gad.276873.115 · DOI
- 1993, Fanconi anemia
- 2012, Molecular pathogenesis and clinical management of Fanconi anemia, J. Clin. Investig., 122, 3799, 10.1172/JCI58321 · DOI · Paper page
- 2019, The Fanconi anemia pathway in cancer, Annu. Rev. Cancer Biol., 3, 457, 10.1146/annurev-cancerbio-030617-050422 · DOI · Paper page
- 2024, Fanconi anemia
- 2021, An update on Fanconi anemia: clinical, cytogenetic and molecular approaches (review), Biomed. Rep., 15, 74, 10.3892/br.2021.1450 · doi:10.3892/br.2021.1450
- 2010, Pathophysiology and management of inherited bone marrow failure syndromes, Blood Rev, 24, 101, 10.1016/j.blre.2010.03.002 · DOI · Paper page
- 2009, Fanconi anemia and its diagnosis, Mutat. Res., 668, 4
- 2016, How I treat MDS and AML in Fanconi anemia, Blood, 127, 2971, 10.1182/blood-2016-01-583625 · DOI
- 1994, Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study, Blood, 84, 1650, 10.1182/blood.V84.5.1650.1650 · DOI · Paper page
- 1983, L'anémie de Fanconi. Fréquence de l'évolution vers la leucémie. [Fanconi's anemia. Incidence of its development into leukemia, Presse Med, 12, 1269
- 1996, Prolonged administration of granulocyte colony-stimulating factor (filgrastim) to patients with Fanconi anemia: a pilot study, Blood, 88, 1588, 10.1182/blood.V88.5.1588.1588 · DOI · Paper page
- 2003, Cancer incidence in persons with Fanconi anemia, Blood, 101, 822, 10.1182/blood-2002-05-1498 · DOI · Paper page
- 2003, Cancer in Fanconi anemia, Blood, 101, 2072, 10.1182/blood-2002-11-3597 · DOI · Paper page
- 2008, Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry, Haematologica, 93, 511, 10.3324/haematol.12234 · DOI · Paper page
- 2003, Cancer in Fanconi anemia, 1927–2001, Cancer, 97, 425, 10.1002/cncr.11046 · DOI · Paper page
- 2010, Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with fanconi anemia: morphologic and cytogenetic characteristics, Am. J. Clin. Pathol., 133, 92, 10.1309/AJCP7W9VMJENZOVG · DOI
- 2011, Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions, Blood, 117, e161, 10.1182/blood-2010-09-308726 · DOI · Paper page
- 2016, The Fanconi anaemia pathway: new players and new functions, Nat. Rev. Mol. Cell Biol., 17, 337, 10.1038/nrm.2016.48 · DOI · Paper page
- 2013, DNA crosslinking damage and cancer—a tale of friend and foe, Transl. Cancer Res., 2, 144
- 2012, Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells, Cell Stem Cell, 11, 36, 10.1016/j.stem.2012.05.013 · DOI · Paper page
- 2012, Damage control and its costs: BM failure in Fanconi anemia stems from overactive p53/p21, Cell Stem Cell, 11, 7, 10.1016/j.stem.2012.06.013 · doi:10.1016/j.stem.2012.06.013
- 2010, The FANCM/FAAP24 complex is required for the DNA interstrand crosslink-induced checkpoint response, Mol. Cell, 39, 259, 10.1016/j.molcel.2010.07.005 · DOI
- 2003, A novel ubiquitin ligase is deficient in Fanconi anemia, Nat. Genet., 35, 165, 10.1038/ng1241 · DOI · Paper page
- 2015, Deficiency of UBE2T, the E2 ubiquitin ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T subtype of Fanconi anemia, Cell Rep, 12, 35, 10.1016/j.celrep.2015.06.014 · DOI
- 2007, A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway, Mol. Cell, 28, 786, 10.1016/j.molcel.2007.09.031 · DOI · Paper page
- 2011, Mutations of the SLX4 gene in Fanconi anemia, Nat. Genet., 43, 142, 10.1038/ng.750 · DOI · Paper page
- 2011, SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype, Nat. Genet., 43, 138, 10.1038/ng.751 · DOI · Paper page
- 2009, Human SLX4 is a Holliday junction resolvase subunit that binds multiple DNA repair/recombination endonucleases, Cell, 138, 78, 10.1016/j.cell.2009.06.029 · DOI · Paper page
- 2008, Mechanism of replication-coupled DNA interstrand crosslink repair, Cell, 134, 969, 10.1016/j.cell.2008.08.030 · DOI · Paper page
- 2016, Involvement of translesion synthesis DNA polymerases in DNA interstrand crosslink repair, DNA Repair, 44, 33, 10.1016/j.dnarep.2016.05.004 · DOI
- 2009, How the Fanconi anemia pathway guards the genome, Annu. Rev. Genet., 43, 223, 10.1146/annurev-genet-102108-134222 · DOI · Paper page
- 2016, Interplay between Fanconi anemia and homologous recombination pathways in genome integrity, EMBO J, 35, 909, 10.15252/embj.201693860 · DOI · Paper page
- 2019, Ribosomopathies: old concepts, new controversies, Trends Genet, 35, 754, 10.1016/j.tig.2019.07.004 · DOI · Paper page
- 2023, Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances, Blood, 141, 1513, 10.1182/blood.2022017739 · DOI
- 2014, Ribosomopathies: mechanisms of disease, Clin. Med. Insights Blood Disord., 7, 7
- 2008, Identification of RPS14 as a 5q− syndrome gene by RNA interference screen, Nature, 451, 335, 10.1038/nature06494 · DOI · Paper page
- 2021, Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy, Signal Transduct. Target. Ther., 6, 323, 10.1038/s41392-021-00728-8 · DOI · Paper page
- 2019, Rare ribosomopathies: insights into mechanisms of cancer, Nat. Rev. Cancer, 19, 228, 10.1038/s41568-019-0105-0 · DOI
- 1988, Multicopy plasmid stability in Escherichia coli requires host-encoded functions that lead to plasmid site-specific recombination, Mol. Gen. Genet., 214, 80, 10.1007/BF00340183 · DOI
- 2017, Ribosomopathies: There's strength in numbers, Science, 358, eaan2755, 10.1126/science.aan2755 · DOI · Paper page
- 2012, Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress, PNAS, 109, 20467, 10.1073/pnas.1218535109 · DOI · Paper page
- 2018, Molecular basis of the human ribosomopathy Shwachman-Diamond syndrome, Adv. Biol. Regul., 67, 109, 10.1016/j.jbior.2017.09.002 · DOI · Paper page
- 2016, DNAJC21 mutations link a cancer-prone bone marrow failure syndrome to corruption in 60S ribosome subunit maturation, Am. J. Hum. Genet., 99, 115, 10.1016/j.ajhg.2016.05.002 · DOI
- 2017, Biallelic mutations in DNAJC21 cause Shwachman-Diamond syndrome, Blood, 129, 1557, 10.1182/blood-2016-08-735431 · doi:10.1182/blood-2016-08-735431
- 2019, EFL1 mutations impair eIF6 release to cause Shwachman-Diamond syndrome, Blood, 134, 277, 10.1182/blood.2018893404 · DOI
- 2021, SRP54 mutations induce congenital neutropenia via dominant-negative effects on XBP1 splicing, Blood, 137, 1340, 10.1182/blood.2020008115 · DOI
- 2017, Mutations in signal recognition particle SRP54 cause syndromic neutropenia with Shwachman-Diamond-like features, J. Clin. Investig., 127, 4090, 10.1172/JCI92876 · DOI · Paper page
- 1993, Diamond-Blackfan anemia
- 2014, Altered translation of GATA1 in Diamond-Blackfan anemia, Nat. Med., 20, 748, 10.1038/nm.3557 · DOI · Paper page
- 2014, Diamond-Blackfan anemia with mandibulofacial dystostosis is heterogeneous, including the novel DBA genes TSR2 and RPS28, Am. J. Med. Genet. A, 164A, 2240
- 2017, Severe congenital neutropenias, Nat. Rev. Dis. Primers, 3, 17032, 10.1038/nrdp.2017.32 · DOI · Paper page
- 2013, Epidemiology of congenital neutropenia, Hematol. Oncol. Clin. North Am., 27, 1
- 2012, Incidence of severe congenital neutropenia in Sweden and risk of evolution to myelodysplastic syndrome/leukaemia, Br. J. Haematol., 158, 363, 10.1111/j.1365-2141.2012.09171.x · doi:10.1111/j.1365-2141.2012.09171.x
- 2006, The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy, Blood, 107, 4628, 10.1182/blood-2005-11-4370 · DOI · Paper page
- 1995, Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia, N. Engl. J. Med., 333, 487, 10.1056/NEJM199508243330804 · DOI · Paper page
- 2007, Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey, Blood, 109, 93, 10.1182/blood-2006-02-004275 · DOI · Paper page
- 2007, Neutrophil elastase in cyclic and severe congenital neutropenia, Blood, 109, 1817, 10.1182/blood-2006-08-019166 · DOI · Paper page
- 2003, Cellular and molecular abnormalities in severe congenital neutropenia predisposing to leukemia, Exp. Hematol., 31, 372, 10.1016/S0301-472X(03)00048-1 · doi:10.1016/s0301-472x(03)00048-1
- 2007, HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease), Nat. Genet., 39, 86, 10.1038/ng1940 · DOI · Paper page
- 2022, Heterozygous variants of CLPB are a cause of severe congenital neutropenia, Blood, 139, 779, 10.1182/blood.2021010762 · DOI
- 2015, Germline mutations in predisposition genes in pediatric cancer. New Engl, J. Med., 373, 2336
- 2021, Genomes for kids: the scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA sequencing, Cancer Discov, 11, 3008, 10.1158/2159-8290.CD-20-1631 · DOI · Paper page
- 2023, Prioritization of patients for germline testing based on tumor profiling of hematopoietic malignancies, Front. Oncol., 13, 1084736, 10.3389/fonc.2023.1084736 · DOI
- 2020, What's germane in the germline? Finding clinically relevant germline variants in myeloid neoplasms from tumor only screening, Leuk. Res., 96, 106431, 10.1016/j.leukres.2020.106431 · DOI
- 2021, Inherited susceptibility to hematopoietic malignancies in the era of precision oncology, JCO Precis. Oncol., 5, 107
- 2014, Bone marrow failure and the telomeropathies, Blood, 124, 2775, 10.1182/blood-2014-05-526285 · DOI · Paper page
- 2018, Fanconi anaemia and cancer: an intricate relationship, Nat. Rev. Cancer, 18, 168, 10.1038/nrc.2017.116 · DOI · Paper page
- 2011, Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells, Blood, 117, 2567, 10.1182/blood-2010-07-295238 · DOI · Paper page
- 2019, Hematologic malignancies and Li–Fraumeni syndrome, Mol. Case Stud., 5, a003210, 10.1101/mcs.a003210 · DOI
- 2016, Acute myeloid leukemia with TP53 germ line mutations, Blood, 128, 2270, 10.1182/blood-2016-08-732610 · DOI
200 of 203 shown
Cited by
The TP53 tumor suppressor gene: From molecular biology to clinical investigations
Baliakas, P., & Soussi, T. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20106 · Cited by 50
Metadata
- Authors
- Liu, Y.-C., Eldomery, M. K., Maciaszek, J. L., & Klco, J. M.
- Affiliations
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA; email: jeffery.klco@stjude.org
- Venue
- Annual Review of Pathology: Mechanisms of Disease
- Publisher
- Annual Reviews
- Published
- 2025-01-24
- Volume
- 20
- Issue
- 1
- Pages
- 87-114
- ISSN
- 1553-4006
- 1553-4014
- Cited by
- 16
- References
- 22
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inherited Predispositions to Myeloid Neoplasms: Pathogenesis and Clinical Implications. https://app.cochat.ai/papers/10.1146/annurev-pathmechdis-111523-023420
- The paper
- Liu, Y.-C., Eldomery, M. K., Maciaszek, J. L., & Klco, J. M. (2025). Inherited Predispositions to Myeloid Neoplasms: Pathogenesis and Clinical Implications. Annual Review of Pathology: Mechanisms of Disease. https://doi.org/10.1146/annurev-pathmechdis-111523-023420
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.